GRI Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.
During the conference, CEO Marc Hertz, PhD shared insights about his leadership journey, his commitment to the company, and his enthusiasm for GRI Bio's development programs. The presentation is now available for viewing on virtualinvestorco.com and the company's investor relations website.
GRI Bio (NASDAQ: GRI), un'azienda biotecnologica specializzata nello sviluppo di modulatori delle cellule Natural Killer T (NKT) per malattie infiammatorie, fibrotiche e autoimmuni, ha annunciato la sua partecipazione alla conferenza virtuale per investitori "What's Your Story" Summer Spotlight On-Demand.
Durante la conferenza, il CEO Marc Hertz, PhD ha condiviso approfondimenti sul suo percorso di leadership, il suo impegno verso l'azienda e il suo entusiasmo per i programmi di sviluppo di GRI Bio. La presentazione è ora disponibile per la visione su virtualinvestorco.com e sul sito web delle relazioni con gli investitori della società.
GRI Bio (NASDAQ: GRI), una empresa biotecnológica centrada en el desarrollo de moduladores de células Natural Killer T (NKT) para enfermedades inflamatorias, fibróticas y autoinmunes, anunció su participación en la conferencia virtual para inversores "What's Your Story" Summer Spotlight On-Demand.
Durante la conferencia, el CEO Marc Hertz, PhD compartió detalles sobre su trayectoria como líder, su compromiso con la empresa y su entusiasmo por los programas de desarrollo de GRI Bio. La presentación ya está disponible para su visualización en virtualinvestorco.com y en el sitio web de relaciones con inversores de la compañía.
GRI Bio (NASDAQ: GRI)는 염증성, 섬유성 및 자가면역 질환을 위한 자연 살해 T세포(NKT) 조절제 개발에 주력하는 생명공학 회사로, 가상 투자자 컨퍼런스 "What's Your Story" Summer Spotlight On-Demand에 참여한다고 발표했습니다.
컨퍼런스에서 CEO Marc Hertz, PhD는 자신의 리더십 여정, 회사에 대한 헌신, 그리고 GRI Bio의 개발 프로그램에 대한 열정을 공유했습니다. 해당 발표는 현재 virtualinvestorco.com과 회사의 투자자 관계 웹사이트에서 시청할 수 있습니다.
GRI Bio (NASDAQ : GRI), une entreprise de biotechnologie spécialisée dans le développement de modulateurs des cellules Natural Killer T (NKT) pour les maladies inflammatoires, fibrosantes et auto-immunes, a annoncé sa participation à la conférence virtuelle pour investisseurs "What's Your Story" Summer Spotlight On-Demand.
Lors de la conférence, le PDG Marc Hertz, PhD a partagé des perspectives sur son parcours de leadership, son engagement envers l'entreprise et son enthousiasme pour les programmes de développement de GRI Bio. La présentation est désormais disponible en replay sur virtualinvestorco.com ainsi que sur le site des relations investisseurs de la société.
GRI Bio (NASDAQ: GRI), ein Biotechnologieunternehmen, das sich auf die Entwicklung von Natural Killer T (NKT)-Zellmodulatoren für entzündliche, fibrotische und autoimmune Erkrankungen spezialisiert hat, gab seine Teilnahme an der virtuellen Investorenkonferenz "What's Your Story" Summer Spotlight On-Demand bekannt.
Während der Konferenz teilte CEO Marc Hertz, PhD Einblicke in seinen Führungsweg, sein Engagement für das Unternehmen und seine Begeisterung für die Entwicklungsprogramme von GRI Bio. Die Präsentation ist jetzt auf virtualinvestorco.com und der Investor-Relations-Website des Unternehmens verfügbar.
- None.
- None.
– Video webcast now available on-demand
LA JOLLA, CA, July 22, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI BIO, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference.
As part of the event, Dr. Hertz dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company’s programs in development.
The on-demand video webcast is now available on virtualinvestorco.com as well as the Events page under the Investors section of the Company’s website (gribio.com).
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
FAQ
When did GRI Bio participate in the Virtual Investor Summer Spotlight Conference?
Who presented for GRI Bio at the Virtual Investor Conference?
What therapeutic areas does GRI Bio (NASDAQ: GRI) focus on?
Where can investors watch GRI Bio's Virtual Investor Conference presentation?
